Should Investors Brace for Bad News From Novavax's Looming Clinical Update?
One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a clinical study. All Novavax did was announce that a call would be held on Monday, July 24, to discuss results from a phase 2 study of its RSV F vaccine.
Based on the stock's surge, investors were obviously viewing the update as a positive development. Despite no mention whatsoever in Novavax's press release about how well its RSV F vaccine performed, many automatically assumed good news. But should investors brace themselves for bad news instead?
Image source: Getty Images.
Source: Fool.com
Novavax Inc. Aktie
12,28 €
13,46 %
Die Novavax Inc. Aktie zieht etwas Aufmerksamkeit auf sich: Mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 21 € für Novavax Inc. signalisiert eine potenzielle Steigerung von über 50% gegenüber dem aktuellen Kurs von 12.28 €.
